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Abstract Favourable clinical results in rheumatoid arthritis
(RA) patients with high disease activity (HDA) are difficult to
achieve. This study evaluated the clinical efficacy of abatacept
according to baseline disease activity compared to adalimumab
and tocilizumab. This study included all patients registered in a
Japanese multicenter registry treated with abatacept (n =214),
adalimumab (n =175), or tocilizumab (n =143) for 24 weeks.
Clinical efficacy of abatacept in patients with HDA (DAS28-
CRP>4.1) and low and moderate disease activity was com-
pared. Clinical efficacy of abatacept, adalimumab, and toci-
lizumab was compared in patients with HDA at baseline. In
patients treated with abatacept, multivariate logistic regression
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identified HDA at baseline as an independent predictor for
achieving low disease activity (LDA; DAS28-CRP<2.7) [OR
0.26, 95 % CI 0.14–0.50] or remission (DAS28-CRP<2.3)
[OR 0.26, 95 % CI 0.12–0.56] at 24 weeks. In patients with
HDA at baseline, logistic regression did not identify treatment
with adalimumab or tocilizumab as independent predictors of
LDA or remission compared to abatacept. Retention rates based
on insufficient efficacy were significantly higher in patients
treated with abatacept compared to adalimumab and lower than
tocilizumab. Retention rates based on adverse events in patients
treated with abatacept were significantly lower compared to
tocilizumab. Clinical efficacy of abatacept was affected by
baseline disease activity. There were no significant differences
between the three different classes of biologics regarding clin-
ical efficacy for treating RA patients with HDA, although
definitive conclusions regarding long-term efficacy will require
further research.
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Introduction
Biological disease-modifying antirheumatic drugs (DMARDs)
are standard treatment for rheumatoid arthritis (RA). Several
clinical trials have demonstrated that biological agents signif-
icantly reduce disease activity and that suppression of synovi-
tis significantly reduces subsequent joint destruction. Howev-
er, favourable clinical results are often difficult to achieve in
patients with high disease activity (HDA), even in this ‘bio-
era’ of drug discovery. Previous reports have demonstrated
that lower disease activity at baseline is a predictor of clinical
efficacy when using anti-tumour necrosis factor (TNF) agents
and tocilizumab, which is a humanized monoclonal antibody
against the interleukin-6 receptor. Hydrich et al. reported that a
lower Disease Activity Score 28 (DAS28) score at baseline
was a significant predictor of clinical remission at 6 months in
patients treated with infliximab and etanercept [1]. The TEM-
PO etanercept study indicated that patients with lower disease
activity at baseline were more likely to achieve remission [2].
Similar results were reported in Japanese RA patients treated
with infliximab, etanercept [3, 4], and tocilizumab. A higher
proportion of patients with moderate disease activity achieved
LDA and clinical remission at week 24 [5].
Abatacept is the first member of a new class of biologic
agents for RA treatment that inhibits T-cell activation by
binding to CD80/86, modulating its interaction with CD28.
This strategy is expected to achieve clinical efficacy in pa-
tients who are naïve or inadequately respond to other classes
of biologics. The efficacy and safety of abatacept has been
reported in several clinical trials [6–10]. The effectiveness of
abatacept has also been reported in clinical practice in Den-
mark and Japan [11, 12]. However, there are no available
reports describing the effects of baseline disease activity on
the clinical efficacy of abatacept. In this study, we evaluated
clinical data of patients treated with abatacept and compared
the clinical efficacy of adalimumab, tocilizumab, and
abatacept in patients with HDA at baseline.
Materials and methods
Participants
All eligible patients were registered in and followed by the
Tsurumai Biologics Communication Registry (TBCR), a RA
research consortium that includes Nagoya University Hospital
and 12 affiliated institutes [13]. TBCRwas initiated in October
2008 to study the long-term efficacy and safety of biologics
used to treat RA. Data were retrospectively collected from
2003 to 2008 and prospectively after 2008. Patient character-
istics and disease activity data are available for all RA patients
treated with commercially available biologics at TBCR insti-
tutes in Japan. Registered data are updated once per year and
include drug continuation, reasons for switching drugs, and
adverse events (e.g. surgery, pregnancy) that may have oc-
curred during treatment. The present study included all patients
who were treated with abatacept (ABT, n =214), adalimumab
(ADA, n =175), or tocilizumab (TCZ, n =143) for 24 weeks at
TBCR-affiliated institutes. All patients met the 1987American
College of Rheumatology classification criteria for RA. Pa-
tients received abatacept infusions three times every 2 weeks
followed by every 4 weeks, adalimumab infusions every
2 weeks, or tocilizumab infusions every 4 weeks according
to drug labels and Japan College of Rheumatology guidelines
for treatment. Patient anonymity was maintained during data
collection, and the security of personal information was strictly
controlled. This study was approved by the Nagoya University
Graduate School of Medicine ethics committee.
Data collection
Data were retrospectively collected from clinical records. The
following demographic data were recorded at the initiation of
treatment (baseline, week 0): disease duration, concomitant
treatment (methotrexate (MTX) or prednisolone (PSL)), joint
damage (Steinbrocker stage), and daily dysfunction
(Steinbrocker class). The following disease parameters were
recorded at baseline and after 4, 12, and 24 weeks of treat-
ment: tender joint count (TJC) and swollen joint count (SJC)
on 28 joints, general health on a visual analogue scale (GH-
VAS), and serum c-reactive protein (CRP) levels. Disease
activity was evaluated at each time point using DAS28 with
CRP (DAS28-CRP).
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Disease activity and EULAR response
Disease activity was categorised as follows: DAS28 remission
(DAS28-CRP<2.3), low disease activity (LDA; 2.3≤DAS28-
CRP<2.7), moderate disease activity (MDA; 2.7≤DAS28-
CRP≤4.1), and high disease activity (HAD; DAS28-CRP>
4.1) [14]. Disease activity was evaluated at baseline and
24weeks after treatment. The European League Against Rheu-
matism (EULAR) response was evaluated at 24 weeks [15].
Statistical analysis
Demographic and disease characteristics are reported using
descriptive statistics. All results are expressed as mean±stan-
dard deviation or percentage. Student’s t test was used for
two-group comparisons, and the chi-square test was used for
categorical variables. The last observation carried forward
(LOCF) method was used in each analysis. To determine
predictors of LDA, clinical remission, and a moderate
EULAR response at 24 weeks, multivariate logistic regression
analysis was performed. All statistical tests were two-sided,
and significance was defined as p <0.05. All analyses were




We compared the clinical parameters of patients with low and
moderate disease activity (≤MDA, DAS28-CRP≤4.1) and
HDA at baseline. Characteristics of patients treated with
abatacept in the ≤MDAandHDAgroups are shown in Table 1.
There were no significant differences in age, RA disease
duration, gender, stage, and class. There were no differences
in the proportion of patients treated concomitantly with MTX
and PSL and mean MTX and PSL doses. Mean DAS28-CRP
and related components (SJC, TJC, CRP, and GH)were higher
in the HDA group, while mean matrix metalloproteinase-3
(MMP-3) values did not differ between groups.
Clinical efficacy and retention in patients treated
with abatacept in the ≤MDA and HDA groups
As shown in Fig. 1a, the mean DAS28-CRP score significant-
ly decreased from baseline to 4 weeks at 3.23±0.64 to 2.95±
0.81 in the ≤ MDA group (p <0.01) and 5.35±0.86 to 4.44±
1.14 in the HDA group (p <0.01). Significant differences in
DAS28-CRP scores were observed between 4 and
12 weeks (4.16±1.24, p <0.01) and 12 and 24 weeks
(3.87±1.33, p <0.01) in the HDA group, while only 4 and
24 weeks (2.74±0.85, p <0.028) in the ≤MDA group. The
difference between the ≤MDA and HDA groups remained
significant at 24 weeks.
Disease activities as assessed by DAS28-CRP score at
baseline and after 24 weeks of abatacept therapy in the
≤MDA and HDA groups are shown in Fig. 1b. The proportion
of patients who achieved LDA gradually increased over time
after initiation of abatacept treatment in the ≤MDA and HDA
groups. The proportion of patients who achieved LDA was
significantly higher in the ≤MDA group (48.8 %) compared to
the HDA group (20.3%, p <0.001). The proportion of patients
who achieved a moderate or good EULAR response was
significantly higher in the HDA group (64.1 %) compared to
the ≤MDA group (40.7 %, p <0.001; Fig. 1c).
Given that multiple confounding factors may contribute to
the clinical efficacy of abatacept, multivariate logistic regres-
sion was performed to confirm the influence of disease activ-
ity at baseline on disease activity at 24 weeks (Table 2). Odds
ratios (ORs) were adjusted for the following parameters: age,
gender, disease duration, class, DAS28-CRP at baseline, prior
use of biologics, and concomitant MTX and PSL use. Multi-
variate analysis confirmed that HDA (DAS28-CRP>4.1) at
baseline, class 3 or 4, and prior use of biologics were inde-
pendent negative factors for achieving LDA or a moderate
EULAR response at 24 weeks.
The retention rate of patients treated with abatacept was
compared between the ≤MDA and HDA groups and analysed
based on reasons for discontinuation. Kaplan–Meier curves
for time to discontinuation due to insufficient efficacy
(insufficiency) and adverse events (AEs) were generated.
Over 24 weeks, 3 of the 86 patients in the ≤MDA group and
16 of the 126 patients in the HDA group withdrew from
abatacept treatment due to insufficiency. The retention rate
based on insufficiency was significantly higher in the ≤MDA
group compared to the HDA group (96.4 vs. 88.4 %, p =
0.023). There were no significant differences in retention rates
due to AEs (95.2 vs. 97.5 %, p =0.226).
Clinical efficacy of abatacept, adalimumab, and tocilizumab
in patients with HDA at baseline
Clinical efficacy of abatacept in patients with HDA was in-
sufficient compared to efficacy in patients with lower activity.
Therefore, we compared the clinical efficacy of abatacept with
agents in different biologic classes in patients with active RA.
RA patients with HDA at baseline were treated with the TNF
inhibitor adalimumab (n =120) and the IL-6R inhibitor toci-
lizumab (n =97).
Table 1 shows baseline characteristics of patients with HDA
treated with abatacept, adalimumab, and tocilizumab. Post hoc
analysis demonstrated that patients treated with abatacept were
significantly older (p <0.001, vs. ADA and TCZ). Fewer pa-
tients treated with adalimumab had a history of being treated
with biologics (p =0.002, vs. ABT; p <0.001, vs. TCZ) and a
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higher proportion concomitantly used MTX (p <0.001, vs.
ABT and TCZ). A lower proportion of patients treated with
abatacept concomitantly used oral steroids (p =0.013, vs.
TCZ). Disease activity parameters (DAS28, TJC, SJC,
CRP, and MMP-3) did not show significant differences,
except for increased GH-VAS in patients treated with abatacept
(p =0.007, vs. TCZ).
As shown in Fig. 2, changes in disease activity parameters
were similar between patients treated with abatacept and
adalimumab throughout the study period. Because clinical
Table 1 Baseline characteristics of rheumatoid arthritis patients who received abatacept and of the patients with high disease activity who received
adalimumab or tocilizumab
Abatacept Adalimumab Tocilizumab
Disease activity at baseline (in patients with HDA)
≤MDA HDA
(n =86) (n =128) p value (n=120) (n =97) p valueb
Age (years) 64.1±11.4 64.9±10.9 0.64 57.3±14.4 55.8±13.8 <0 .001
Gender (% female) 82.6 80.5 0.725 82.5 78.4 0.761
Disease duration (years) 10.9±10.1 13.0±10.8 0.177 13.8±10.6 10.7±8.9 0.074
Stage (I/II/III/IV %) 11.6/26.7/34.9/26.7 10.2/12.5/41.4/35.9 0.052 12.5/15.0/30.0/42.5 13.4/23.7/24.7/38.1 0.097
Class (I/II/III/IV %) 11.6/45.3/41.9/1.2 3.2/45.3/48.4/3.1 0.071 8.3/50.8/37.5/3.3 12.4/44.3/43.3/0.0 0.069
Prior use of biologics (%) 51.2 52.3 0.89 32.5 62.9 <0 .001
MTX use (%) 51.2 48.4 0.781 76.7 36.1 <0 .001
MTX dose (mg/week)a 7.3±2.5 7.2±2.3 0.79 7.0±1.9 7.9±1.6 0.106
Oral steroid use (%) 52.3 54.7 0.779 60.8 71.9 0 .041
Oral steroid dose (mg/day)a 4.2±2.0 4.4±2.3 0.643 5.2±2.7 4.8±2.1 0.181
MMP-3 (ng/mL) 226.9±746.5 276.7±271.6 0.568 335.1±365.1 378.1±307.8 0.066
SJC, 0-28 2.7±3.0 7.2±5.9 <0 .001 7.9±5.5 8.2±5.9 0.357
TJC, 0-28 2.7±2.4 10.4±7.2 <0 .001 9.2±6.3 10.5±7.6 0.345
CRP (mg/dL) 0.9±1.3 3.1±3.2 <0 .001 3.7±3.3 3.7±2.9 0.257
GH, VAS 0–100 mm 32.8±20.8 70.4±20.1 <0 .001 64.6±20.6 61.5±23.6 0 .007
DAS28-CRP 3.2±0.6 5.4±0.9 <0 .001 5.3±0.9 5.5±1.0 0.656
Data are presented as mean±standard deviation except when otherwise indicated
Stage Steinbrocker’s stages,Class Steinbrocker’s classes,MTX methotrexate,MMP-3 matrix metalloproteinase-3, SJC swollen joint count, TJC tender
joint count, CRP c-reactive protein, GH general health, VAS visual analog scale, DAS28 Disease Activity Score in 28 joints
aMean among patients receiving the drug
bObtained from analysis of variance (ANOVA) between Abatacept (HDA), Adalimumab, and Tocilizumab groups
Fig. 1 a Clinical efficacy of abatacept in rheumatoid arthritis patients.
Mean and standard deviation for the Disease Activity Score based on 28
joints (DAS28-CRP). §p <0.01 between the HDA and ≤MDA groups. b
Changes in DAS28-CRP defined disease activity over 24 weeks of
abatacept treatment. High DAS28-CRP>4.1, Moderate 4.1≥DAS28-
CRP≥2.7, Low 2.7>DAS28-CRP≥2.3, Remission DAS28-CRP<2.3.
c Comparison of European League Against Rheumatism (EULAR)
responses at 24 weeks between patients with high disease activity at
baseline (HDA) and patients with lower disease activity (≤MDA) at
baseline. *p <0.05; **p<0.01
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data at 4 and 12 weeks were unavailable for patients treated
with tocilizumab, we only show data at baseline and 24weeks.
ANOVA demonstrated significant differences in TJC (p =
0.029), CRP (p =0.004), and MMP-3 (p =0.036) at 24 weeks
between the three treatments. Post hoc analysis (Bonferroni
method) showed a significant difference in TJC between
abatacept and adalimumab (6.5±7.0 vs. 4.4±5.1, p =0.029)
and CRP and MMP-3 between adalimumab and tocilizumab
(1.8±2.5 vs. 0.76±2.1, p =0.003; 219.1±373.3 vs. 130.8±
102.8, p =0.048, respectively).
The proportion of patients who achieved LDA, clinical
remission, a moderate or good EULAR response, and a good
EULAR response at 24 weeks was compared following treat-
ment with abatacept, adalimumab, and tocilizumab (Fig. 3).
Table 2 Multivariate logistic regression analysis for the achievement of
low disease activity (LDA), clinical remission, and moderate or good
EULAR response at 24 weeks in the overall patients using abatacept
(upper column) or in the patients with high disease activity at baseline
using abatacept, adalimumab, or tocilizumab (lower column)
LDA at 24 weeks Remission at 24 weeks Moderate or good EULAR
response at 24 weeks
Adjusted OR (95 % CI) p value Adjusted OR (95% CI) p value Adjusted OR (95% CI) p value
Overall patients taking abatacept
DAS28-CRP>4.1 0.261 (0.135–0.503) <0 .001 0.264 (0.124–0.564) 0 .001 3.010 (1.626–5.574) <0 .001
Steinbrocker class 1–2 (vears 3–4) 2.427 (1.145–5.147) 0 .021 2.003 (0.853–4.707) 0.111 1.670 (0.841–3.318) 0.143
No previous use of biologics 2.346 (1.185–4.642) 0 .014 2.056 (0.938–4.508) 0.072 2.824 (1.520–5.250) 0 .001
Concomitant MTX use 0.698 (0.353–1.381) 0.302 0.652 (0.299–1.425) 0.284 0.798 (0.433–1.472) 0.47
Patients with HDA at baseline
Adalimumab use (vs abatacept) 1.361 (0.683–2.711) 0.381 1.611 (0.712–3.648) 0.252 0.740 (0.402–1.363) 0.334
Tocilizumab use (vs abatacept) 1.479 (0.733–2.983) 0.275 1.057 (0.430–2.598) 0.904 2.594 (1.316–5.114) 0 .006
DAS28-CRP score at baseline 0.768 ( 0.551–1.070) 0.119 0.600 (0.386–0.933) 0 .023 0.929 (0.700–1.232) 0.608
Steinbrocker class 1–2 (vears 3–4) 2.809 (1.570–5.029) 0 .001 3.254 (1.509–7.019) 0 .003 1.830 (1.119–2.994) 0 .016
No previous use of biologics 2.030 (1.187–3.473) 0 .01 3.070 (1.558–6.049) 0 .001 2.152 (1.299–3.567) 0 .003
Concomitant MTX use 0.934 (0.522–1.672) 0.818 1.102 (0.543–2.237) 0.788 1.157 (0.676–1.982) 0.594
OR odds ratio, CI confidence interval, EULAR European League Against Rheumatism, DAS28 Disease Activity Score in 28 joints,MTX methotrexate
Fig. 2 Overall clinical efficacy of abatacept (ABT), adalimumab
(ADA), and tocilizumab (TCZ) in rheumatoid arthritis patients
with high disease activity at baseline. Mean and standard devia-
tions for the Disease Activity Score based on 28 joints (DAS28-
CRP) and tender joint count (TJC), swollen joint count (SJC),
general health on a visual analogue scale (GH-VAS), c-reactive
protein (CRP), and matrix metalloproteinase-3 (MMP-3) are
shown
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There was no significant difference in the proportion of pa-
tients who achieved LDA at 24 weeks. Although a lower
proportion of patients treated with abatacept achieved clinical
remission compared to adalimumab, the difference was not
significant compared to tocilizumab. A higher proportion of
patients treated with tocilizumab achieved a moderate or good
EULAR response compared to patients treated with abatacept
and adalimumab. There was no significant difference in the
proportion of patients who achieved a good EULAR response
between the three groups.
Multivariate analysis confirmed that none of the three bio-
logics had significant advantages in achieving LDA or clinical
remission at 24 weeks (Table 2). Adalimumab was not an
independent factor for achieving LDA, remission, or a moderate
EULAR response at 24weeks. Tocilizumabwas an independent
factor for achieving a moderate EULAR response at 24 weeks
compared to abatacept. Class 1 or 2 and no prior history of
biologic use were independent factors for LDA, remission, and
a moderate EULAR response. ORs were adjusted for the fol-
lowing parameters: age, gender, disease duration, class, DAS-
CRP at baseline, prior biologic use, and concomitant MTX and
PSL treatment.
Retention rates in patients with HDA at baseline treated
with abatacept, adalimumab, and tocilizumab
Retention rates were evaluated based on reasons for discon-
tinuation. Kaplan–Meier curves for time to discontinuation for
each agent due to insufficient efficacy and AEs are shown in
Fig. 4a, b, respectively. Retention rates due to insufficient
efficacy in patients treated with abatacept were significantly
higher than in patients treated with adalimumab and lower
than in patients treated with tocilizumab. Retention rates due
to AEs in patients treated with abatacept were significantly
lower than in patients treated with tocilizumab.
Discussion
Baseline disease activity had a significant influence on the
clinical efficacy of abatacept. In patients with HDA, the
clinical efficacy of abatacept appeared to be insufficient com-
pared with efficacy in patients with a lower disease activity.
The clinical efficacy of abatacept in HDA patients was similar
to the efficacy of adalimumab and tocilizumab. Some physi-
cians perceive abatacept as being difficult to use in RA pa-
tients with HDA due to insufficient efficacy. However, ade-
quate clinical responses were not obtained in any of the
patients evaluated, regardless of the class of biologic used.
Based on the present data, abatacept can be selected to treat
RA patients with low, moderate, and high disease activity.
A recent head-to-head clinical trial (AMPLE trial) demon-
strated that subcutaneous abatacept was not inferior to
adalimumab [16]. The ADACTA head-to-head trial reported
that tocilizumab monotherapy was superior to adalimumab
monotherapy in reducing RA activity in patients for whom
MTX was ineffective or inappropriate [17]. Although the data
suggest equivalent clinical efficacies between different classes
of biologics, patients in these trials were generally uniform
and are different from real-world patients with diverse char-
acteristics seen in clinical practice. The Danish DANBIO
registry reported similar abatacept and tocilizumab efficacies
in RA patients in clinical practice [11]. Multicenter registries
can provide real-world long-term data relevant to safety,
Fig. 3 Proportion of patients who
achieved DAS28-CRP defined as
low disease activity (LDA),
clinical remission, good or
moderate EULAR response, and
good EULAR response. *p<0.05;
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efficacy, or future outcomes in patients with comorbidities.
The value of such registries in accumulating and evaluating
relevant data cannot be underestimated.
In this study, differences in the DAS28-CRP score between
patients treated with abatacept in the ≤MDA and HDA groups
were consistent throughout the study period and remained
significant at 24 weeks. The proportion of patients who
achieved LDA or remission at 24 weeks was significantly
lower in the HDA group. Multivariate regression analysis
demonstrated that HDA at baseline was an independent nega-
tive predictor for achieving LDA and remission. Abatacept
treatment in patients with HDA appeared to yield poor clinical
results. However, similar results have been reported in previous
studies related to TNF inhibitors and tocilizumab [1–5, 18].
Thus, inferior clinical efficacy in HDA patients is not abatacept
specific, but is likely due to common features of DMARDs.
The proportion of patients who achieved a moderate or good
EULAR response was higher in the HDA group at 24 weeks.
There was a sharp downward trend in the HDA group between
12 and 24 weeks, whereas the trend was gradual in the ≤MDA
group after 4 weeks. A longer period is necessary to evaluate
whether disease activity in the HDA group can eventually
correspond to activity in the ≤MDA group.
Clinical efficacy in patients with HDAwas similar between
abatacept, adalimumab, and tocilizumab. This is the first study
to demonstrate the clinical efficacy of three different classes of
biologics in RA patients with HDA in clinical practice from
the TBCR. Given that neither adalimumab nor tocilizumab
were independent factors for achieving LDA or remission
compared with abatacept, we suggest that there are no signif-
icant differences between the three biologics regarding clinical
efficacy for HDA RA. However, several differences were
observed. Tocilizumab treatment resulted in a higher propor-
tion of patients who achieved a moderate EULAR response at
24 weeks and was an independent factor for a moderate
EULAR response at 24 weeks compared to abatacept.
Cytokine-blocking biologics, specifically tocilizumab, led to
normal acute phase reactants (e.g. CRP or ESR) in almost all
patients. While this constitutes a positive treatment effect,
improvement in CRP might lead to an overestimation of the
EULAR response rate based on DAS28-CRP [19]. Abatacept
had an average discontinuation rate due to insufficient clinical
efficacy. Adalimumab had the highest discontinuation rate due
to insufficiency despite a higher proportion of biologic-naïve
patients and concomitant MTX use compared to abatacept and
tocilizumab, which could be due to relatively lowMTX doses
in Japan compared to doses used in European countries and
the USA. It will be necessary to study patients treated with
higher doses of MTX in the future. Tocilizumab had the
lowest discontinuation rate due to insufficiency despite having
the lowest proportion of biologic-naïve patients and concom-
itant MTX use. This could be partially explained by a higher
rate of achieving a EULAR response, which generally encour-
ages physicians to continue treatment even if clinical efficacy
appears to be inadequate. It will be necessary to study whether
low discontinuation rates can bemaintained for longer periods
of time. In contrast, tocilizumab demonstrated the highest
discontinuation rate due to adverse events compared to
abatacept. Abatacept satisfactorily balances clinical efficacy
and safety in RA patients with HDA.
‘Biologic-naïve’ was an independent factor for achieving
LDA or EULAR responses at 24 weeks in patients treated
with abatacept. Similar to other classes of biologics, abatacept
likely demonstrates optimal efficacy in biologic-naïve pa-
tients. Several reports have indicated that adalimumab or
tocilizumab demonstrate higher efficacy in biologic-naïve
patients compared to patients with a history of prior biologic
use [5, 20–26]. Advanced functional impairment has also been
reported as a negative factor regarding clinical efficacy of
adalimumab and tocilizumab [1, 18, 27, 28]. ‘Better physical
function’ in all patients treated with abatacept was an inde-
pendent factor for achieving LDA. In patients with HDA at
baseline using abatacept, adalimumab, or tocilizumab, ‘bio-
logic-naïve’ or ‘better physical function’ were independent
factors for achieving LDA or remission rather than the specific
agent used. Thus, baseline characteristics are more critical
Fig. 4 Kaplan–Meier curves for time to discontinuation for each biologic. Withdrawal was due to a insufficient clinical efficacy (insufficiency) and b
adverse events. Retention rates were compared using the log-rank test among groups. ABT abatacept, ADA adalimumab, TCZ tocilizumab
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than treatment agents for predicting favourable clinical effica-
cy in RA patients with HDA.
This study has several limitations. It was observational and
not randomised, and treatments were likely influenced by
patient characteristics and other factors such as preference of
administration routes. Although concomitant MTX use was
not an independent factor for achieving LDA, remission, or a
moderate EULAR response in all patients treated with
abatacept and patients with HDA treated with abatacept,
adalimumab, or tocilizumab, the mean MTX dose was rela-
tively low in this study. Future studies with higher MTX doses
are necessary to conclude whether MTX has a synergistic
effect. In addition, radiographic data were not available. Due
to the importance of joint protective effects in demonstrating
clinical efficacy, evaluating radiographic changes in patients
treated with abatacept will be necessary in the future.
In conclusion, this study demonstrated the clinical efficacy
of abatacept, adalimumab, and tocilizumab in clinical practice.
The clinical efficacy in RA patients with HDA was similar
between the three classes of biologics. We suggest that
abatacept can be used to treat patients with low, moderate,
and high disease activity in clinical practice.
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